9605 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Reports Second Quarter 2026 Operational Highlights and Financial Results
Theriva™ Biologics Doses First Patient in VIRAGE2 Trial for VCN-01 in Pancreatic Cancer
News, Material Contracts
Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Annual Report to Security Holders
Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
Other Events
Reports First Quarter 2026 Operational Highlights and Financial Results
Q2
FY 2025
Q3
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Correspondence